Seeking Alpha
 

CytRx Corporation (CYTR)

- NASDAQ
  • Fri, May. 1, 10:51 AM
    • CytRx (CYTR -13%) Q1 results: Revenues: $0; R&D Expense: $12.6M (+80.0%); SG&A: $3.1M (unch); Operating Loss: ($15.7M) (-55.4%); Net Loss: ($17.5M) (-472.3%); Loss Per Share: ($0.31) (-487.5%); Quick Assets: $65.2M (-16.2%).
    • No guidance given.
    | Comment!
  • Fri, May. 1, 9:42 AM
    | Comment!
  • Tue, Mar. 10, 6:36 AM
    • CytRx (CYTR -0.9%) FY14 results: Revenues: $0.1M (-66.7%); R&D Expense: $36.7M (+109.7%); SG&A: $12.8M (+24.3%); Operating Loss: ($49.6M) (-79.7%); Net Loss: ($30.1M) (+36.6%); Loss Per Share: ($0.55) (+61.8%); Quick Assets: $77.8M (+101.6%).
    • No guidance given.
    | Comment!
  • Tue, Mar. 10, 6:12 AM
    | Comment!
  • Nov. 4, 2014, 6:06 AM
    • CytRx (NASDAQ:CYTR): Q3 EPS of -$0.10 may not be comparable to consensus of -$0.25.
    • Press Release
    | 1 Comment
  • Aug. 6, 2014, 8:01 AM
    • CytRx Corp. (NASDAQ:CYTR) Q2 results: Revenue: $0; Operating Expenses: $13.3M (+107.8%); Operating Loss: ($13.3M) (-107.8%); Net Loss: ($15.7M) (-361.8%); Loss Per Share: ($0.28) (-154.5%); Quick Assets: $102.5M (+165.5%).
    • No guidance given.
    | Comment!
  • Aug. 6, 2014, 6:17 AM
    • CytRx Corporation (NASDAQ:CYTR): Q2 EPS of -$0.28 may not be comparable to consensus of -$0.20.
    • Press Release
    | 1 Comment
  • May. 1, 2014, 7:46 AM
    • CytRx (CYTR): Q1 EPS of $0.09 may not be comparable to consensus of  -$0.18.
    • Press Release
    | 1 Comment
  • Mar. 5, 2014, 7:33 AM
    • CytRx (CYTR) set to begin global phase 3 trial for aldoxorubicin as a second-line treatment for soft tissue sarcoma (STS) after the phase 2 trial demonstrated 80 - 100% superiority of doxorubicin in median progression-free survival (PFS), 6-month PFS and overall response rate.
    • Under a Special Protocol Assessment from the FDA, the phase 3 trial will target STS patients who have relapsed or are refractory following prior chemotherapy treatment. In January, the FDA approved continued dosing until disease progression.
    • Two phase trials are underway for assess the safety and efficacy of aldoxorubicin in patients with unresectable glioblastoma multiforme and Kaposi's sarcoma.
    • Quick assets totaled $38.5M at years end.
    • The company raised $86M in a secondary offering last month.
    • Mutual fund ownership has increased from 21 to 25 over the past 4 quarters.
    | 1 Comment
  • Oct. 29, 2013, 6:11 AM
    • CytRx (CYTR): Q3 EPS of -$0.33 misses by $0.11.(PR)
    | 1 Comment
  • Aug. 6, 2013, 8:59 AM
    • CytRx (CYTR): Q2 EPS of -$0.11 beats by $0.08.
    • Revenue of $200K.
    | Comment!
  • May. 9, 2013, 9:24 AM
    CytRx (CYTR): Q1 EPS of -$0.23 misses by $0.08. (PR)
    | Comment!
Visit Seeking Alpha's
CYTR vs. ETF Alternatives
Company Description
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.
Sector: Healthcare
Industry: Biotechnology
Country: United States